Loading...
Market
How many doses of the updated mRNA COVID-19 vaccine will be administered in Japan by March 31, 2025?
2
Resolution / Starting Odds
Less than 10 million • 25%
10-20 million • 25%
21-30 million • 25%
More than 30 million • 25%
Japan's Ministry of Health, Labor and Welfare official reports
Story
Japan Approves CSL and Arcturus Therapeutics' Updated mRNA COVID-19 Vaccine for JN.1 Strain, Distributed by Meiji Seika Pharma
Sep 13, 2024, 12:04 PM
Japan's Ministry of Health, Labor and Welfare has approved CSL and Arcturus Therapeutics' updated self-amplifying mRNA COVID-19 vaccine for protection against the JN.1 strain. The vaccine will be distributed in Japan by Meiji Seika Pharma. This approval marks a significant step in Japan's efforts to combat the ongoing pandemic, leveraging advanced mRNA technology to enhance immunity against emerging strains. CSL and Meiji Seika Pharma are key players in this initiative.
View original story
Similar markets
Continued use without changes • 25%
Usage restrictions for certain age groups • 25%
Temporary suspension • 25%
Permanent ban • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
New regulations on mRNA vaccines • 25%
Public health advisory • 25%
No action taken • 25%
Further studies commissioned • 25%
Less than 5 million • 25%
5 million to 10 million • 25%
10 million to 15 million • 25%
More than 15 million • 25%
Less than 1 million • 25%
1-5 million • 25%
5-10 million • 25%
More than 10 million • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
Less than 50,000 • 25%
50,000 to 99,999 • 25%
100,000 to 150,000 • 25%
More than 150,000 • 25%
0-5 million doses • 25%
5.1-10 million doses • 25%
10.1-15 million doses • 25%
15.1+ million doses • 25%
High (>70%) • 25%
Moderate (50-70%) • 25%
Low (30-50%) • 25%
Very Low (<30%) • 25%
Yes • 50%
No • 50%
